SNOA - Sonoma Pharmaceuticals Inc Stock Price, Fair Value and News

0.28USD+0.03 (+12.00%)Delayed as of 17 May 2024, 09:55 am ET

Market Summary

USD0.28+0.03

Delayedas of 17 May 2024, 09:55 am

12.00%

SNOA Stock Price

View Fullscreen

SNOA RSI Chart

SNOA Valuation

Market Cap

3.9M

Price/Earnings (Trailing)

-0.77

Price/Sales (Trailing)

0.32

EV/EBITDA

-0.3

Price/Free Cashflow

-0.75

SNOA Price/Sales (Trailing)

SNOA Profitability

Operating Margin

18.03%

EBT Margin

-41.52%

Return on Equity

-75.85%

Return on Assets

-34.72%

Free Cashflow Yield

-133.3%

SNOA Fundamentals

SNOA Revenue

Revenue (TTM)

12.3M

Rev. Growth (Yr)

6.59%

Rev. Growth (Qtr)

14.9%

SNOA Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

55.34%

Earnings Growth (Qtr)

41.64%

Breaking Down SNOA Revenue

52 Week Range

0.251.52

(Low)(High)

Last 7 days

66.7%

Last 30 days

47.1%

Last 90 days

56.3%

Trailing 12 Months

-75.5%

How does SNOA drawdown profile look like?

SNOA Financial Health

Current Ratio

4.07

Debt/Equity

Debt/Cashflow

-332.73

SNOA Investor Care

Shares Dilution (1Y)

235.70%

Diluted EPS (TTM)

-0.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.3M	12.7M	12.1M	12.3M
2022	12.6M	12.9M	12.5M	12.6M
2021	18.6M	16.5M	14.5M	12.5M
2020	17.9M	19.2M	20.2M	20.8M
2019	19.0M	19.1M	18.9M	18.0M
2018	16.7M	17.2M	17.8M	18.2M
2017	12.8M	14.0M	15.5M	17.0M
2016	12.8M	11.8M	10.5M	11.4M
2015	13.9M	14.1M	14.9M	14.2M
2014	13.7M	13.7M	12.9M	12.8M
2013	15.5M	14.8M	14.3M	14.1M
2012	12.7M	13.9M	14.7M	15.5M
2011	9.8M	10.4M	11.6M	12.1M
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sonoma Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 30, 2023	thornton bruce	acquired	-	-	100,000	executive vice president
Jun 30, 2023	trombly amy moss	acquired	-	-	100,000	chief executive officer
Apr 23, 2020	dal poggetto john	acquired	-	-	3,086	chief financial officer
Apr 23, 2020	edwards robert grant	acquired	-	-	2,609	chief financial officer

Which funds bought or sold SNOA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-342	4,044	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-2.00	14.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-1.00	7.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	25.87	276	1,989	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	2,241	2,241	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-59.19	-3,589	2,165	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-1,824	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-21,067	-	-%
May 13, 2024	HRT FINANCIAL LP	sold off	-100	-5,000	-	-%
May 13, 2024	XTX Topco Ltd	new	-	2,738	2,738	-%

Are Funds Buying or Selling SNOA?

Are funds buying SNOA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNOA

No. of Funds

Recent SEC filings of Sonoma Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	424B3	Prospectus Filed
Feb 08, 2024	10-Q	Quarterly Report

Peers (Alternatives to Sonoma Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	371.3B	85.6B	6.80%	-2.97%	9.65	4.33	5.68%	202.39%
MRK	331.6B	61.4B	4.69%	14.08%	143.8	5.4	6.11%	-82.30%
AMGN	168.9B	29.5B	18.50%	39.89%	44.87	5.72	12.76%	-52.47%
PFE	163.9B	57.8B	12.61%	-21.28%	130.78	2.84	76.51%	-86.81%
GILD	84.6B	27.4B	0.85%	-13.87%	174.55	3.08	1.51%	-91.32%
TEVA	18.5B	16.0B	24.52%	100.49%	-37.33	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	2.99%	-21.03%	9.53	2.4	54.01%	364.56%
PRGO	4.1B	4.6B	0.47%	-8.40%	-532.89	0.9	-0.06%	94.55%
BHC	2.6B	9.0B	-19.11%	-5.35%	-5.7	0.29	10.01%	-27.45%
AMPH	2.1B	676.2M	4.47%	-0.56%	13.51	3.09	30.38%	66.04%
SMALL-CAP
TLRY	1.6B	743.2M	16.39%	-11.62%	-4.68	2.22	24.65%	80.36%
TXMD	24.2M	1.3M	10.53%	-49.88%	-3.27	18.6	-98.14%	-104.71%
ACRX	19.7M	89.6M	13.73%	58.80%	-1.39	0.19	287.27%	-129.41%
AGRX	2.6M	21.5M	2.56%	-90.89%	-0.34	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Sonoma Pharmaceuticals Inc News

Latest updates

Sonoma Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	14.9%	3,138,000	2,731,000	3,427,000	3,014,000	2,944,000	3,331,000	3,983,000	2,298,000	2,902,000	3,744,000	3,684,000	2,157,000	4,936,000	5,769,000	5,767,000	4,311,500	4,395,000	4,727,000	4,495,000	4,382,000	5,280,000
Gross Profit	47.5%	1,460,000	990,000	1,204,000	664,000	831,000	1,536,000	1,646,000	96,000	1,203,000	1,241,000	1,453,000	-193,500	1,995,000	2,502,000	2,255,000	1,653,000	2,001,000	2,175,000	2,293,000	1,875,000	2,847,000
Operating Expenses	4.8%	2,304,000	2,198,000	2,444,000	1,812,500	2,665,000	2,267,000	2,501,000	3,156,500	2,161,000	2,205,000	2,357,000	2,621,000	2,133,000	2,333,000	2,920,000	4,877,000	3,109,000	3,462,000	4,064,000	4,579,000	5,197,000
S&GA Expenses	2.5%	1,703,000	1,662,000	2,119,000	1,811,500	2,665,000	2,067,000	2,295,000	3,152,000	2,135,000	2,195,000	2,273,000	2,490,500	2,100,000	2,418,000	2,444,000	4,394,000	2,861,000	3,192,000	3,726,000	4,252,000	4,746,000
R&D Expenses	12.1%	601,000	536,000	325,000	1,000	-	200,000	206,000	4,500	26,000	10,000	84,000	130,500	33,000	-85,000	476,000	483,000	248,000	270,000	338,000	327,000	451,000
EBITDA Margin	18.2%	-0.40	-0.49	-0.44	-0.38	-0.55	-0.47	-0.39	-0.42	-0.30	-0.25	-0.22	-0.20	-0.16	-	-	-	-	-	-	-	-
Interest Expenses	0%	5,000	5,000	5,000	6,000	1,000	3,000	4,000	-8,500	3,000	-4,000	-1,000	2,000	-2,000	4,000	-	3,000	1,000	2,000	10,000	7,000	7,000
Income Taxes	-130.6%	-57,000	186,000	-33,000	-131,500	34,000	100,000	-35,000	-337,500	-	5,000	-	713,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	28.9%	-923,000	-1,298,000	-1,451,000	-1,439,500	-1,905,000	-917,000	-922,000	-3,281,500	-944,000	-95,000	-1,098,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	17.4%	-0.42	-0.50	-0.45	-0.39	-0.56	-0.48	-0.41	-0.43	-0.31	-0.27	-0.24	-0.21	-0.17	-	-	-	-	-	-	-	-
Net Income	41.6%	-866,000	-1,484,000	-1,418,000	-1,308,000	-1,939,000	-1,017,000	-887,000	-2,944,000	-944,000	-100,000	-1,098,000	-3,660,000	-650,000	120,000	240,000	-1,736,000	-1,084,000	-1,203,000	715,000	-3,222,000	-2,298,000
Net Income Margin	18.8%	-0.41	-0.51	-0.45	-0.39	-0.54	-0.46	-0.38	-0.40	-0.46	-0.38	-0.32	-0.21	-0.10	-	-	-	-	-	-	-	-
Free Cashflow	10.4%	-1,105,000	-1,233,000	-232,000	-2,631,000	-379,000	-1,855,000	-1,556,000	-1,457,000	-327,000	-1,329,000	-1,272,000	-1,481,000	669,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	7.2%	14,618	13,635	15,893	16,231	13,928	14,962	17,158	18,845	19,347	19,828	14,121	14,987	18,231	18,145	18,083	14,561	16,496	16,145	16,918	14,448	17,045
Current Assets	8.6%	12,502	11,516	13,587	13,798	11,232	12,393	14,817	16,430	17,699	18,021	12,157	12,983	16,212	16,267	16,520	12,283	13,858	13,310	13,834	12,496	14,579
Cash Equivalents	12.6%	2,406	2,137	3,544	3,820	2,634	3,351	5,586	7,396	8,529	8,392	2,811	4,220	5,541	4,320	4,551	3,691	3,727	3,232	4,284	3,689	6,496
Inventory	17.6%	2,955	2,513	2,730	2,858	2,849	3,025	2,788	2,663	2,879	2,482	2,620	2,530	2,958	3,704	4,193	2,181	2,825	3,098	3,368	3,409	3,215
Net PPE	-8.3%	397	433	485	488	314	305	309	320	299	337	373	360	404	370	372	365	483	526	564	727	817
Liabilities	-0.4%	7,926	7,960	8,651	8,254	8,369	7,941	9,199	10,148	8,178	8,368	9,500	9,624	5,915	6,583	7,418	8,937	5,287	5,874	5,414	3,959	3,705
Current Liabilities	-5.1%	3,074	3,239	4,041	3,717	3,934	3,527	4,854	5,819	3,875	4,078	5,233	4,078	3,883	4,569	5,647	4,729	4,158	4,686	4,135	3,591	3,325
Long Term Debt	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	1,310	1,310	1,310	1,310	-	-	-	-	12.00	14.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	596	-	49.00	265	481	-	106	211	322	8.00
LT Debt, Non Current	-	-	-	-	-	15.00	15.00	15.00	-	-	-	-	1,310	1,310	1,310	1,310	-	-	-	-	12.00	14.00
Shareholder's Equity	17.9%	6,692	5,675	7,242	7,977	5,559	7,021	7,959	8,697	11,169	11,460	4,621	5,363	12,316	11,562	10,665	5,624	11,209	10,271	11,504	7,770	13,340
Retained Earnings	-0.5%	-193,282	-192,416	-190,932	-189,514	-188,206	-186,267	-185,250	-184,363	-181,419	-180,475	-180,375	-179,277	-172,536	-171,886	-172,006	-175,327	-170,869	-169,785	-168,582	-169,238	-166,016
Additional Paid-In Capital	0.8%	202,795	201,210	201,076	200,904	197,939	197,697	197,584	197,370	197,156	196,438	189,266	189,217	189,085	188,701	188,112	186,559	186,257	184,499	184,366	184,074	183,772
Shares Outstanding	164.2%	13,684	5,179	5,142	4,934	3,107	3,103	3,101	3,101	2,093	3,005	2,093	2,093	2,079	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	6,580,267	-	-	-	16,659	-	-	-	16,929	-	-	-	7,559	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.3%	-1,104	-1,231	-215	-2,441	-348	-1,830	-1,533	-1,395	-326	-1,304	-1,223	-1,476	746	-357	-2,291	-3,591	-840	-898	738	-2,746	-2,364
Share Based Compensation	7.7%	140	130	177	100	242	113	214	212	56.00	55.00	59.00	55.00	93.00	160	63.00	302	112	133	292	360	402
Cashflow From Investing	50.0%	-1.00	-2.00	-17.00	-82.00	34.00	-187	-23.00	-61.00	-	11.00	-49.00	-4.00	-83.00	-79.00	554	3,680	33.00	-57.00	-12.00	-8.00	-28.00
Cashflow From Financing	1121.7%	1,318	-129	-135	3,372	-318	-178	-387	222	463	6,920	-209	269	242	213	2,584	-	1,270	-105	-136	-80.00	4,897

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNOA Income Statement

2023-12-31

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 3,138	$ 2,944	$ 9,296	$ 10,258
Cost of revenues	1,678	2,113	5,642	6,645
Gross profit	1,460	831	3,654	3,613
Operating expenses
Research and development	601	0	1,462	6
Selling, general and administrative	1,703	2,665	5,484	7,030
Total operating expenses	2,304	2,665	6,946	7,036
Loss from operations	(844)	(1,834)	(3,292)	(3,423)
Other expense, net	(79)	(71)	(380)	(322)
Loss before income taxes	(923)	(1,905)	(3,672)	(3,745)
Income tax benefit (expense)	57	(34)	(96)	(98)
Net loss	(866)	(1,939)	(3,768)	(3,843)
Other comprehensive loss
Net loss	(866)	(1,939)	(3,768)	(3,843)
Foreign currency translation adjustments	297	235	595	136
Comprehensive loss	$ (569)	$ (1,704)	$ (3,173)	$ (3,707)

SNOA Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,406	$ 3,820
Accounts receivable, net	2,876	2,572
Inventories, net	2,955	2,858
Prepaid expenses and other current assets	4,009	4,308
Current portion of deferred consideration, net of discount	256	240
Total current assets	12,502	13,798
Property and equipment, net	397	488
Operating lease, right of use assets	341	418
Deferred tax asset	922	949
Deferred consideration, net of discount, less current portion	378	505
Other assets	78	73
Total assets	14,618	16,231
Current liabilities:
Accounts payable	864	841
Accrued expenses and other current liabilities	1,847	2,029
Deferred revenue	75	100
Deferred revenue Invekra	63	60
Short-term debt	44	431
Operating lease liabilities	181	256
Total current liabilities	3,074	3,717
Long-term deferred revenue Invekra	101	140
Withholding tax payable	4,591	4,235
Operating lease liabilities, less current portion	160	162
Total liabilities	7,926	8,254
Commitments and Contingencies (Note 5)
Stockholders’ Equity
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2023 and March 31, 2023, respectively, no shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively	0	0
Common stock, $0.0001 par value; 24,000,000 shares authorized at December 31, 2023 and March 31, 2023, respectively, 13,684,333 and 4,933,550 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively (Note 7)	2	5
Additional paid-in capital	202,795	200,904
Accumulated deficit	(193,282)	(189,514)
Accumulated other comprehensive loss	(2,823)	(3,418)
Total stockholders’ equity	6,692	7,977
Total liabilities and stockholders’ equity	$ 14,618	$ 16,231

About Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

CEO	Ms. Amy M. Trombly
WEBSITE	sonomapharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	9

Sonoma Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Sonoma Pharmaceuticals Inc? What does SNOA stand for in stocks?

SNOA is the stock ticker symbol of Sonoma Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sonoma Pharmaceuticals Inc (SNOA)?

As of Thu May 16 2024, market cap of Sonoma Pharmaceuticals Inc is 3.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNOA stock?

You can check SNOA's fair value in chart for subscribers.

What is the fair value of SNOA stock?

You can check SNOA's fair value in chart for subscribers. The fair value of Sonoma Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sonoma Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNOA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sonoma Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNOA is over valued or under valued. Whether Sonoma Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Sonoma Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNOA.

What is Sonoma Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SNOA's PE ratio (Price to Earnings) is -0.77 and Price to Sales (PS) ratio is 0.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNOA PE ratio will change depending on the future growth rate expectations of investors.